A designer bow-tie combination therapeutic platform: An approach to resistant cancer treatment by simultaneous delivery of cytotoxic and anti-inflammatory agents and radiation
- 1 December 2018
- journal article
- research article
- Published by Elsevier in Biomaterials
- Vol. 187, 117-129
Abstract
No abstract availableKeywords
Funding Information
- Sylvester Comprehensive Cancer Center
- Department of Defense Prostate Cancer Idea (W81XWH-12-1-0406)
- Florida Department of Health (8BC10)
- Department of Radiation Oncology
- Sylvester Comprehensive Cancer Center
- Sylvester Comprehensive Cancer Center
This publication has 66 references indexed in Scilit:
- Redox homeostasis: the linchpin in stem cell self-renewal and differentiationCell Death & Disease, 2013
- HER2-Associated Radioresistance of Breast Cancer Stem Cells Isolated from HER2-Negative Breast Cancer CellsClinical Cancer Research, 2012
- Engineering of blended nanoparticle platform for delivery of mitochondria-acting therapeuticsProceedings of the National Academy of Sciences, 2012
- New Strategies in Metastatic Prostate Cancer: Targeting the Androgen Receptor Signaling PathwayClinical Cancer Research, 2011
- Targeted delivery of a cisplatin prodrug for safer and more effective prostate cancer therapy in vivoProceedings of the National Academy of Sciences, 2011
- Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA–PEG nanoparticlesProceedings of the National Academy of Sciences, 2008
- Synthesis and Evaluation of Technetium-99m- and Rhenium-Labeled Inhibitors of the Prostate-Specific Membrane Antigen (PSMA)Journal of Medicinal Chemistry, 2008
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancersNature, 2008
- Host-derived RANKL is responsible for osteolysis in a C4-2 human prostate cancer xenograft model of experimental bone metastasesBMC Cancer, 2007
- Inflammation in prostate carcinogenesisNature Reviews Cancer, 2007